ASX Healthcare ETFs for 2026
The healthcare sector is likely to be a long-term winner due to ageing populations and continuous medical innovation which is why it should be a part of most investment portfolios.
The following three ASX healthcare ETFs are good picks for investors looking to gain diversified exposure to the healthcare sector.
The iShares Global Healthcare ETF (ASX: IXJ)
The iShares Global Healthcare ETF (ASX: IXJ) is a solid option among ASX healthcare ETFs because it gives exposure to many global healthcare companies. These include pharmaceutical, biotechnology and medical device companies around the world.
The ETF charges an annual management fee of 0.41%. Its goal is to track the S&P Global 1200 Healthcare Sector Index which gives investors access to some of the largest healthcare companies through a single investment.
Over past five years, the ETF has delivered annualised returns of about 9.43% which shows the long-term strength of the healthcare sector.
The portfolio holds major global companies such as Eli Lilly, Johnson & Johnson, AbbVie, Roche and AstraZeneca which are among the largest healthcare companies in the world.
The VanEck Global Healthcare Leaders ETF (ASX: HLTH)
The VanEck Global Healthcare Leaders ETF (ASX: HLTH) gives exposure to 50 fundamentally strong global healthcare companies that are attractively valued and have good growth prospects.
It invests across pharmaceuticals, biotechnology, healthcare equipment and services which gives diversified exposure to the global healthcare sector.
The portfolio is equally weighted which reduces concentration risk and creates balanced exposure across major healthcare leaders.
The management fee is 0.45% and the long-term outlook for the sector remains strong because of rising healthcare spending and innovation in biotechnology and medical research which could support future growth for the ETF.
The Betashares Global Healthcare Currency Hedged ETF (ASX: DRUG)
The Betashares Global Healthcare Currency Hedged ETF (ASX: DRUG) is a well-known ASX healthcare ETF which gives exposure to large global healthcare companies outside Australia while it also hedges currency risk.
Major holdings include Johnson & Johnson, Pfizer and Roche which are among the largest healthcare companies in the world.
The ETF has a management fee of 0.47% and estimated additional expenses of 0.10% which makes it a relatively cost-effective way to access global healthcare companies.
As of 27 February 2026, the portfolio holds 60 companies and this global diversification with currency hedging makes DRUG a strong long-term portfolio diversifier.
(Source: Company Reports)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
